Skip to content

May 7, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Commercial
Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales

Commercial

Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales

BioSpace

Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk's Wegovy pill.

Metabolic & GLP-1

Read full story

pharminent May 6, 2026 (Last updated: May 7, 2026)

BioSpace

Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk’s Wegovy pill.

Metabolic & GLP-1

Read full story

Post navigation

Previous: CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026

Next: FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight

Related Stories

Commercial

Novo hikes guidance on Wegovy pill’s fast sales start

pharminent May 6, 2026

Commercial

Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat

pharminent May 5, 2026

Commercial

Odyssey eyes $236M for renewed Nasdaq bid, Seaport docks on Nasdaq

pharminent May 4, 2026

You May Have Missed

Regulatory

FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit

pharminent May 7, 2026

M&A / Deals

Angelini inks $4.1B Catalyst buy to enter US rare disease market

pharminent May 7, 2026

Regulatory

Bayer plans filings for cardiac amyloidosis imaging agent

pharminent May 7, 2026

M&A / Deals

Roche buys AI-powered diagnostics player PathAI

pharminent May 7, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.